REG - BiVictriX Therapcts. - Proposed Voluntary Delisting

Bivictrix TherapeuticsAnnouncement

12/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240812:nRSL9863Za&default-theme=true

RNS Number : 9863Z  BiVictriX Therapeutics PLC  12 August 2024

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of
the European Union (Withdrawal) Act 2018. With the publication of this
announcement via a Regulatory Information Service, this inside information is
now considered to be in the public domain.

 

NOT FOR PUBLICATION OR RELEASE IN OR INTO THE UNITED STATES OR AUSTRALIA,
CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH
AFRICA, OR ANY PROVINCE OR TERRITORY THEREOF OR TO OR FOR THE ACCOUNT OF ANY
NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES OR ANY PERSON RESIDENT IN
AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC
OF SOUTH AFRICA.

 

BiVictriX Therapeutics plc

 

("BiVictriX", "BiVictriX Therapeutics" or the "Company")

 

Proposed voluntary cancellation of admission of Ordinary Shares to trading on
AIM

Proposed re-registration as a Private Limited Company

Adoption of New Articles

And

Notice of General Meeting

 

Alderley Park, 12 August 2024 - BiVictriX (AIM: BVX), a drug discovery and
development company applying an innovative, proprietary approach to develop a
new class of highly selective, next generation cancer therapeutics, bispecific
antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior potency,
whilst reducing treatment-related toxicities, today announces the proposed
cancellation of the admission of its ordinary shares of £0.01 each ("Ordinary
Shares") from trading on AIM (the "Cancellation") and the re-registration of
the Company as a private limited company (the "Re-registration").

 

A circular ("Circular") will be sent to Shareholders today, setting out the
background to and reasons for the Cancellation and the Re-registration. The
Company is seeking Shareholder approval for the Cancellation and
Re-registration at a general meeting, which has been convened for 11:30 a.m.
on 29 August 2024 at the Company's registered office, Mereside Alderley Park,
Alderley Edge, Manchester SK10 4TG ("General Meeting"), notice of which is
included in the Circular. The Company is also seeking Shareholder approval at
the General Meeting for the adoption of new articles of association (the "New
Articles") to be effective on the Re-registration.

 

If the Cancellation Resolution is passed at the General Meeting, it is
anticipated that the Cancellation will become effective at 7:00 a.m. on 11
September 2024. The Cancellation Resolution is conditional, pursuant to
Rule 41 of the AIM Rules, upon the approval of Shareholders holding not less
than 75 per cent. of the votes cast by Shareholders (whether present in person
or by proxy) at the General Meeting.

 

The Company has received irrevocable undertakings from DBW Investments, Robert
Keith, Alderley Park Ventures Limited, BioCity Investments Limited, Alden AS
and those Directors who are also Shareholders, as set out below, representing
in aggregate approximately 42.5 per cent. of the Company's issued share
capital, to vote in favour of the Resolutions set out in the Circular.

 

Tiffany Thorn, CEO of BiVictriX Therapeutics, said: "With a growing pipeline
of novel, first-in-class bispecific Antibody Drug Conjugates ("bsADC"),
together with a highly competitive platform in one of the most commercially
attractive sectors across the entirety of the oncology drug development
market, BiVictriX is well positioned to capitalise on its already strong
foundations. To maintain our competitive advantage within this space, we
intend to progress our pipeline and platform expeditiously, and after
extensive review, the Board has concluded that this will be best achieved by
the Company delisting from AIM and re-registering as a private company.

 

I'm immensely proud of everything BiVictriX has achieved to date. Yet the
Board has concluded that the current public market valuation does not reflect
the scale of our potential. The Directors believe that, as a private company,
BiVictriX is likely to have access to a larger quantum of future funding, to
enable the business to meet key value inflection points. We therefore believe
the Cancellation is in the best interest of Shareholders and the future of our
business as a whole."

 

Proposed Cancellation and Re-registration

 

In view of the Company's ambitions to move BVX001 into the clinic at pace, the
Company has spent time considering a variety of funding options alongside its
opportunities for early partnership of BVX001 and, consequently, has conducted
an extensive review of the benefits and drawbacks to the Company retaining the
admission of its Ordinary Shares to trading on AIM. The Directors believe that
Cancellation and Re-registration is in the best interest of the Company and
its Shareholders as a whole. In reaching this conclusion, the Directors have
considered the following key factors:

 

·      Challenges as a pre-clinical stage business in a difficult
fundraising environment: Notwithstanding the Company's positive momentum
across BVX001 and BVX002 and positive initial FDA interactions regarding
moving BVX001 into the clinic, the Company is at a pre-clinical stage of
development and requires significant funds to be able to proceed towards a
Phase I clinical trial and associated dose manufacturing. As at 30 June 2024,
the Company had cash and cash equivalents of £1.7 million. The Board does not
believe that its current market capitalisation, nor current equity market
conditions, will support a sufficient fundraise (on terms acceptable to
Shareholders, or at all) to enable the Company to progress these plans in the
short term or potentially the medium term. The Directors believe that whilst a
'top up raise' may be possible (whilst the Ordinary Shares remain admitted to
trading on AIM), due to the current market conditions, the Directors believe
this is likely to be challenging and may not ultimately result in significant
value creation. The Directors also believe the likely amount from any funding
that may be accessible in the short to medium term (whilst the Ordinary Shares
are admitted to trading on AIM) is unlikely to provide the Company with
sufficient scale to allow further progression of BVX001 towards an IND
submission or development of the Company's broader portfolio, nor provide a
strong capital base to support strategic discussions. On the contrary, Myricx
Bio, a UK private company, announced on 8 July 2024 that it had raised £90
million to take their programmes into the clinic. The Directors note that
Myricx Bio is at a similar stage to BiVictriX and believe this transaction
illustrates the appetite for major investors to invest in this area.

 

·      Market capitalisation not reflective of progress and prospects:
In comparison to private companies operating in the ADC space, the Directors
believe the current market capitalisation of the Company neither fully
reflects the positive achievements nor the underlying prospects of the
business and is a barrier to future growth, funding and potential partnership
and licensing discussions.

 

·      Current valuation impacting potential for partnerships and
collaborations: The Company has continued to build key external relationships
including with industry partners. Ongoing and further work with these key
partners is expected to provide multiple opportunities for future
manufacturing, clinical and commercialisation alliances to optimise the value
potential of BiVictriX as a whole. However, the Directors believe that the
Company's profile and negotiating ability is severely constrained by the
Company's current market capitalisation, small scale and limited cash
reserves.

 

·      Identifying how best to benefit from market interest in ADCs: The
Company notes that whilst there has been significant activity in the ADC
space, the majority of ADC partnership and license opportunities occur either
following initial clinical data on the asset in question or on earlier-stage
assets being developed within well-capitalised, clinical stage companies. Many
of the transactions occurring in the ADC space attract upfront payments which
are multiples of the Company's current market capitalisation. Whilst there is
no guarantee that Cancellation will lead to the Company successfully
completing a significant fundraise and/or partnership transaction (in BVX001
and/or other pipeline assets), the Directors believe the Company's prospects
of successfully completing such transactions will be significantly increased
by obtaining early clinical proof-of-concept data on the wider platform.
Currently the Board believe this would be best achieved through the further
progression of BVX001 to IND and into the clinic, which, as noted above, will
require a significant fundraise which the Board believe is more likely to be
achieved successfully as a private company without the constraints of a public
listing. The Company believes being a private company will facilitate a
greater degree of flexibility in the Company's strategy for delivering
shareholder value.

 

·      Need for greater diversity of investors: The Directors believe
that as a private company, BiVictriX will have access to a greater pool of
investors who are more likely to support clinical development, allowing more
rapid development across its portfolio; and providing significant balance
sheet strength whilst the Company continues its engagement with potential
partners and collaborators. The Directors believe these factors, alongside an
increase of scale of the business, have the potential to deliver increased
opportunity for the creation of significant Shareholder value. This pool of
investors is likely to include venture capital and specialist investors, who
the Directors believe may have greater appetite for investing companies such
as BiVictriX who do not have regular revenue streams and who are subject to
research, development and clinical trial costs and risk.

 

·      Seeking out opportunities for US investment bank engagement: The
Company plans to engage a US healthcare investment bank with significant
experience in the ADC space to assist the Company in securing additional
capital to support its operations, although there can be no assurance that the
Company will be successful in this regard.

 

·      Assessing the best route for a significant fundraise: Whilst
there is no guarantee that Cancellation and Re-registration will lead to the
Company successfully completing a significant fundraise or licensing deal, the
Directors believe its prospects of such a transaction will be significantly
increased as a private company. The Board notes a number of recent examples of
significant fundraises for pre-clinical private companies operating in the ADC
space, including the recent £90 million raise for Myricx Bio noted above.

 

·      Current challenges regarding liquidity: The Directors believe the
current levels of liquidity in trading of the Company's Ordinary Shares on AIM
do not, in itself, offer investors the opportunity to trade in meaningful
volumes or with frequency within an active market.

 

·      Regulatory, financial and time burden related to AIM listing: The
considerable cost of maintaining admission to trading on AIM, including fees
payable to its professional advisers, including its nominated adviser and
joint brokers, AIM fees payable to the London Stock Exchange as well as
incremental legal, insurance, accounting and auditing fees, along with the
considerable amount of management time and regulatory burden associated with
maintaining the Company's admission to trading on AIM are, in the Directors'
opinion, disproportionate to the benefits to the Company. The Directors
believe the time and cost savings associated with the Cancellation and
Re-registration could be better utilised for the benefit of the Company and
value creation for its Shareholders. Subject to the Cancellation and excluding
manufacturing and clinical trial costs for BVX001, the Company has sufficient
funds for working capital into the second half of 2025.

 

·      Support for delisting from largest shareholders: The Company has
obtained irrevocable commitments for the Cancellation and Re-registration from
its largest Shareholders representing in aggregate approximately 39.6 per
cent. of the Company's current issued share capital.

 

The Company is making arrangements for a Matched Bargain Facility to assist
Shareholders to trade in the Ordinary Shares to be put in place from the date
of the Cancellation, if the Resolutions are passed. The Matched Bargain
Facility will be provided by JP Jenkins. JP Jenkins is an appointed
representative of Prosper Capital LLP, which is authorised and regulated by
the FCA.

 

A copy of this announcement and the Circular will be made available on the
Company's website later today at www.bivictrix.com (http://www.bivictrix.com)
.

 

Capitalised terms used but not defined in this announcement shall have the
same meaning given to such term in the Circular.

 

For more information, please contact:

 BiVictriX Therapeutics plc

 Tiffany Thorn, Chief Executive Officer                         Email: info@bivictrix.com

 Michael Kauffman, Non-Executive Chairman

 SP Angel Corporate Finance LLP (NOMAD and Broker)
 David Hignell, Caroline Rowe (Corporate Finance)

Vadim Alexandre, Rob Rees (Sales and Broking)                Tel: +44 (0) 20 3470 0470

 Panmure Liberum Limited (Joint Broker)
 Emma Earl, Freddy Crossley, Mark Rogers, Rupert Dearden

                                                               Tel: +44 (0) 20 3100 2000

 ICR Consilium

 Namrata Taak, Lucy Featherstone, Max Bennett, Emmalee Hoppe   Tel: +44 (0) 20 3709 5700

                                                               Email: Bivictrix@consilium-comms.com

About BiVictriX Therapeutics plc

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical
experience and its proprietary discovery engine to advance a new class of
highly cancer-selective, next-generation precision cancer therapies in one of
the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni®
Antibody Drug Conjugates ("ADCs") combine superior efficacy with substantially
improved cancer-selectivity and safety to provide opportunities for prolonged
dosing and greater efficacy in the clinic. The Company is advancing its
pipeline to deliver the future of cancer care across a broad range of
haematological and solid cancer indications in areas of high unmet medical
need.

Find out more at www.bivictrix.com (http://www.bivictrix.com/)  and connect
with us on LinkedIn
(https://www.linkedin.com/company/bivictrix-therapeutics-plc/)  and
Twitter @BiVictriX (https://twitter.com/BiVictriX) .

 

 

APPENDIX I

 

Extracts from the Circular

 

 

 

Background and Strategic Context

 

The Company's Ordinary Shares have been admitted to trading on AIM since its
initial public offering ("IPO") in August 2021, and during this time the
Company has raised gross proceeds of c.£9.6 million through equity fundraises
to support the ongoing requirements and growth of the business.

Following the Company's promising preclinical safety and efficacy data for its
lead product, BVX001, and continued progression and expansion of the target
discovery platform, the Directors have continued to consider the Company's
opportunities to generate Shareholder value and the optimal capital structure
to deliver this. The Directors believe that having access to a larger quantum
of funding than has historically been available to the Company through its AIM
listing would allow it to pursue a greater number of opportunities to reach
key value inflexion points. In particular, the Directors believe that the
BVX001 data achieved to date supports progression of BVX001 into the clinic,
subject to significant funding requirements. The Company is also mindful that
the optimal opportunity for a significant license/partner deal for BVX001
and/or other pipeline assets will be with a strengthened balance sheet, a
higher valuation and potentially on the back of initial clinical efficacy
data.

Notwithstanding the Company's current intention to progress BVX001 into the
clinic, the Board will continue to review all opportunities available to it to
create Shareholder value.

The Directors believe that as a private company, BiVictriX may have access to
a wider range of investors which could include specialist investors in the US
with the potential opportunity to raise funds at a higher valuation than the
current market capitalisation of the Company. The Directors have based this
decision on a combination of factors, including: the Company's current market
capitalisation, the difficult equity market conditions for pre-revenue
companies, the low trading liquidity of its Ordinary Shares, as well as the
Group being at pre-clinical stage. These factors combined mean that the
opportunity for significant value creation is currently tempered, and
accordingly the Directors believe that the Cancellation is in the best
interests of Shareholders. Further details as to the reasons for the
Cancellation are set out in Paragraph 3 of this Part I below.

Following the Cancellation and Re-registration, the Company will continue to
review the structure and composition of the business, the Board and the
executive management team, to ensure the optimal corporate structure is in
place to support the long-term success of the Company.

 

Process for, and principal effects of, the Cancellation

 

The Directors are aware that certain Shareholders may be unable or unwilling
to hold Ordinary Shares in the event that the Cancellation is approved and
becomes effective. Such Shareholders should consider selling their interests
in the market prior to the Cancellation becoming effective. However, should
the Cancellation become effective, the Company intends to implement a Matched
Bargain Facility with a third party which would facilitate Shareholders buying
and selling Ordinary Shares on a matched bargain basis following Cancellation.

 

Under the AIM Rules, the Company is required to give at least 20 clear
Business Days' notice of the Cancellation. Additionally, the Cancellation will
not take effect until at least five clear Business Days have passed following
the passing of the Cancellation Resolution. If the Cancellation Resolution is
passed at the General Meeting, it is proposed that the last day of trading in
the Ordinary Shares on AIM will be 10 September 2024 and that the
Cancellation will take effect at 7:00 a.m. on 11 September 2024.

 

If the Cancellation becomes effective, SP Angel will cease to be the nominated
adviser of the Company and the Company will no longer be required to comply
with the AIM Rules.

 

Under the AIM Rules, it is a requirement that the Cancellation must be
approved by Shareholders holding not less than 75 per cent. of votes cast by
Shareholders at the General Meeting. Accordingly, the Notice of General
Meeting, set out in at the end of the Circular, contains a special resolution
to approve the Cancellation.

 

The principal effects of the Cancellation will include the following:

·      as a private company, there will be no formal market mechanism
enabling Shareholders to trade Ordinary Shares (other than any limited
off-market mechanism provided by the Matched Bargain Facility), and no price
will be publicly quoted for the Ordinary Shares;

·      it is possible that, following the publication of this
announcement, the liquidity and marketability of the Ordinary Shares may be
significantly reduced, and their value adversely affected (however, as set out
above, the Directors believe that the existing liquidity in the Ordinary
Shares is, in any event, limited);

·      the Ordinary Shares may be more difficult to sell compared to
shares of companies traded on AIM (or any other recognised market or trading
exchange);

·      in the absence of a formal market and quoted price, it may be
difficult for Shareholders to determine the market value of their investment
in the Company at any given time;

·      the regulatory and financial reporting regime applicable to
companies whose shares are admitted to trading on AIM will no longer apply,
albeit the Company will remain subject to the Takeover Code;

·      Shareholders will no longer be afforded the protections given by
the AIM Rules, such as the requirement to be notified of price sensitive
information or certain events and the requirement that the Company seek
shareholder approval for certain corporate actions, where applicable,
including substantial transactions, reverse takeovers, related party
transactions and fundamental changes in the Company's business, including
certain acquisitions and disposals;

·      the levels of disclosure and corporate governance within the
Company may not be as stringent as for a company quoted on AIM;

·      the Company will no longer be subject to UK MAR regulating inside
information and other matters;

·      the Company will no longer be required to publicly disclose any
change in major shareholdings in the Company under the Disclosure Guidance and
Transparency Rules;

·      SP Angel will cease to be nominated adviser to the Company;

·      whilst the Company's CREST facility will remain in place
immediately post the Cancellation, the Company's CREST facility may be
cancelled in the future and, although the Ordinary Shares will remain
transferable, they may cease to be transferable through CREST (in which case,
Shareholders who hold Ordinary Shares in CREST will receive share
certificates);

·      stamp duty will be due on transfers of shares and agreements to
transfer shares unless a relevant exemption or relief applies to a particular
transfer; and

·      the Cancellation and Re-registration may have personal taxation
consequences for Shareholders. Shareholders who are in any doubt about their
tax position should consult their own professional independent tax adviser.

The above considerations are not exhaustive, and Shareholders should seek
their own independent advice when assessing the likely impact of the
Cancellation on them.

 

For the avoidance of doubt, the Company will remain registered with the
Registrar of Companies in England and Wales in accordance with, and subject
to, the Companies Act, notwithstanding the Cancellation and Re-registration.
The Resolutions to be proposed at the General Meeting include the adoption of
the New Articles, with effect from the Re-registration. A copy of the New
Articles can be viewed at www.bivictrix.com (http://www.bivictrix.com) and is
included at Appendix 1 to the Circular.

 

Transactions in the Ordinary Shares prior to and post the proposed
Cancellation

 

Prior to the Cancellation

 

Shareholders should note that they are able to continue trading in the
Ordinary Shares on AIM prior to the Cancellation.

 

Following the Cancellation

 

The Company is making arrangements for a Matched Bargain Facility to assist
Shareholders to trade in the Ordinary Shares to be put in place from the date
of the Cancellation, if the Resolutions are passed. The Matched Bargain
Facility will be provided by JP Jenkins. JP Jenkins is an appointed
representative of Prosper Capital LLP, which is authorised and regulated by
the FCA.

 

Under the Matched Bargain Facility, Shareholders or persons wishing to acquire
or dispose of Ordinary Shares will be able to leave an indication with JP
Jenkins, through their stockbroker (JP Jenkins is unable to deal directly with
members of the public), of the number of Ordinary Shares that they are
prepared to buy or sell at an agreed price. In the event that JP Jenkins is
able to match that order with an opposite sell or buy instruction, it would
contact both parties and then effect the bargain (trade). Shareholdings remain
in CREST and can be traded during normal business hours via a UK regulated
stockbroker. Should the Cancellation become effective, and the Company puts in
place the Matched Bargain Facility, details will be made available to
Shareholders on the Company's website at www.bivictrix.com
(http://www.bivictrix.com) .

 

The Matched Bargain Facility will operate for a minimum of six months after
the Cancellation. The Directors' current intention is that it will continue
beyond that time, but Shareholders should note that it could be withdrawn and
therefore inhibit the ability to trade the Ordinary Shares. Further details
will be communicated to the Shareholders at the relevant time.

 

If Shareholders wish to buy or sell Ordinary Shares on AIM, they must do so
prior to the Cancellation becoming effective. As noted above, in the event
that Shareholders approve the Cancellation, it is anticipated that the last
day of dealings in the Ordinary Shares on AIM will be 10 September 2024 and
that the effective date of the Cancellation will be 11 September 2024.

 

 

Process for the Re-Registration

 

As set out above, following the Cancellation, the Directors believe that the
requirements and associated costs of the Company maintaining its public
company status will be difficult to justify and that the Company will benefit
from the more flexible requirements and lower costs associated with private
limited company status. It is therefore proposed to Re-register the Company as
a private limited company. In connection with the Re-registration, it is
proposed that the New Articles be adopted to reflect the change in the
Company's status to a private limited company. The principal effects of the
Re-registration and the adoption of the New Articles on the rights and
obligations of Shareholders and the Company are summarised in Part II of the
Circular. A copy of the New Articles can be found at Appendix 1 to the
Circular.

 

Under the Companies Act, the Re-registration and the adoption of the New
Articles must be approved by Shareholders holding not less than 75 per cent.
of votes cast by Shareholders at the General Meeting. Accordingly, the Notice
of General Meeting set out at the end of the Circular contains a special
resolution to approve the Re-registration and adopt the New Articles.

 

If the Cancellation Resolution and the Re-registration Resolution are approved
at the General Meeting, an application will be made to the Registrar of
Companies for the Company to be re-registered as a private limited company.
Re-registration will take effect when the Registrar of Companies issues a
certificate of incorporation on Re-registration. The Registrar of Companies
will issue the certificate of incorporation on Re-registration when it is
satisfied that no valid application can be made to cancel the Re-registration
Resolution or that any such application to cancel the Re-registration
Resolution has been determined and confirmed by the Court.

 

If the Resolutions are passed at the General Meeting, it is anticipated that
the Re-registration will become effective before the end of September 2024.

 

Takeover Code

 

The Takeover Code applies to all offers for companies which have their
registered offices in the United Kingdom, the Channel Islands or the Isle of
Man if any of their equity share capital or other transferable securities
carrying voting rights are admitted to trading on a UK regulated market or a
UK multilateral trading facility or on any stock exchange in the Channel
Islands or the Isle of Man.

 

The Takeover Code also applies to all offers for companies (both public and
private) which have their registered offices in the United Kingdom, the
Channel Islands or the Isle of Man and which are considered by the Panel to
have their place of central management and control in the United Kingdom, the
Channel Islands or the Isle of Man, but in relation to private companies only
if one of a number of conditions is met, for example, if the Company's shares
were admitted to trading on a UK regulated market or a UK multilateral trading
facility or on any stock exchange in the Channel Islands or the Isle of Man at
any time in the preceding ten years.

 

If the Cancellation and Re-registration are approved by Shareholders at the
General Meeting, the Company will be re-registered as a private company and
its securities will no longer be admitted to trading on a regulated market or
a multilateral trading facility in the United Kingdom. In these circumstances,
the Takeover Code will only apply to the Company if it is considered by the
Panel to have its place of central management and control in the United
Kingdom, the Channel Islands or the Isle of Man. This is known as the
"residency test". In determining whether the residency test is satisfied, the
Panel has regard primarily to whether a majority of a company's directors are
resident in these jurisdictions.

 

On the basis of the current composition and residency of the Directors, the
residency test will be satisfied, therefore the Company is considered by the
Panel to have its place of central management and control in the United
Kingdom, the Channel Islands or the Isle of Man. Consequently, the Takeover
Code will continue to apply to the Company following the Cancellation and the
Re-registration subject to its terms until the later of:

 

·      the date falling 10 years following the effective date of the
Cancellation;

·      the date falling 10 years after dealings and/or prices at which
persons are willing to deal in any of the Ordinary Shares have been published
on a regular basis for a continuous period of at least six months, whether via
a newspaper, electronic price quotation system or otherwise;

·      the date falling 10 years after any of the Ordinary Shares have
been subject to a marketing arrangement as described in section 693(3)(b) of
the Companies Act; or

·      the date falling 10 years after the Company has filed a
prospectus for the offer, admission to trading or issue of securities with the
registrar of companies or any other relevant authority in the United Kingdom,
the Channel Islands or the Isle of Man,

provided that, the Takeover Code may cease to apply earlier, if any changes to
the composition of the Board results in the majority of the Directors not
being resident in the United Kingdom, Channel Islands or Isle of Man.

 

Should the Takeover Code cease to apply to the Company in the future,
Shareholders would not be afforded the protections provided by the Takeover
Code. This includes the requirement for a mandatory cash offer to be made if
either:

 

·     a person acquires an interest in shares which, when taken together
with the shares in which persons acting in concert with it are interested,
increases the percentage of shares carrying voting rights in which it is
interested to 30 per cent. or more; or

·     a person, together with persons acting in concert with it, is
interested in shares which in the aggregate carry not less than 30 per cent.
of the voting rights of a company but does not hold shares carrying more than
50 per cent. of such voting rights and such person, or any person acting in
concert with it, acquires an interest in any other shares which increases the
percentage of shares carrying voting rights in which it is interested.

 

Before giving your consent to the Cancellation and the Re-registration, you
may want to take independent professional advice from an appropriate
independent financial adviser.

 

 

 

 

APPENDIX II

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

 

 Event                                                               Time and/or date((1)(2))

 Publication and posting of the Circular                             12 August 2024

 Latest time for receipt of proxy appointments in respect of the     11:30am on 27 August 2024

 General Meeting

 General Meeting                                                     11:30am on 29 August 2024

 Announcement of result of General Meeting                           29 August 2024

 Last day of dealings in Ordinary Shares on AIM                      10 September 2024

 Cancellation of admission of the Ordinary Shares to trading on AIM  7:00am on 11 September 2024

 Matched Bargain Facility for Ordinary Shares commences              11 September 2024

 Expected re-registration as a private company                       week commencing 23 September 2024

 

Notes:

 

(1)        All of the times referred to in this announcement refer to
London time, unless otherwise stated.

(2)        The timetable above assumes that the Resolutions set out in
the Notice of General Meeting are passed. Events listed in the above timetable
following the General Meeting are conditional on the Resolutions being passed
at the General Meeting without amendment.

(3)        Each of the times and dates in the above timetable is
subject to change. If any of the above times and/or dates change, the revised
times and dates will be notified to Shareholders by an announcement through a
Regulatory Information Service.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUAARUPCGRG